Noluthando Mwelase - Concepedia

Author

Noluthando Mwelase

University of the Witwatersrand ORCID

Also Known As

Hakim, James, Larisha Pillay-Ramaya, N Mwelase, Noluthando H. Mwelase, Noluthando Mwelase

Publications

909

Citations

H-Index

Concepts

All Affiliations

University of the Witwatersrand Johns Hopkins University University of Zimbabwe Fundação Oswaldo Cruz Johns Hopkins Medicine

About

Noluthando Mwelase is an author at University of the Witwatersrand specializing in hiv, medicine, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	122
2	Public Health	1	1	35
3	Epidemiology	1	1	35
4	Immunology	1	1	35
5	Pathology	1	1	87

Noluthando Mwelase

Publications

855

Citations

H-Index

Page 1

	Year	Citations
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis Susan Swindells, Ritesh Ramchandani, Amita Gupta, New England Journal of Medicine	2019	347
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial Kelly E. Dooley, Richard Kaplan, Noluthando Mwelase, Clinical Infectious Diseases	2019	108
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial Susan E. Krown, Carlee Moser, Patrick MacPhail, The Lancet Treatment And PreventionResource-limited SettingsPathologyNon-inferiority TrialHiv	2020	87
Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study Mark W. Tenforde, Ashish Yadav, David W. Dowdy, JAIDS Journal of Acquired Immune Deficiency Syndromes	2017	40
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial Jean‐Michel Molina, Birgit Grund, Fred M. Gordin, The Lancet HIV Primary ImmunodeficiencyEpidemiologyAntiretroviral TherapyHiv/aids CounsellingTreatment And Prevention	2018	35
As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial Mina C. Hosseinipour, Minhee Kang, Susan E. Krown, Clinical Infectious Diseases	2018	35
Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings Fiona P. Havers, Barbara Detrick, Sandra Wagner Cardoso, PLoS ONE	2014	32
Virologic outcomes in early antiretroviral treatment: HPTN 052 Susan H. Eshleman, Ethan Wilson, Xinyi C. Zhang, HIV Clinical Trials	2017	28
C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings Mark W. Tenforde, Nikhil Gupte, David W. Dowdy, PLoS ONE	2015	26
Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation Rupak Shivakoti, Wei-Teng Yang, Nikhil Gupte, Clinical Infectious Diseases	2015	23

Page 1